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Survival analysisCDK inhibitors CDKN1B (p27) and CDKN2A (p16) inhibit cell cycle progression. A lower expression level of
only p27 has been correlated with poorer prognosis in various types of clinical cancers. The difference may be
the result of distinct genes downstream of these CDK inhibitors. Here, we report that NF-Y transcription
factor-targeted genes speciﬁcally down-regulated by p27 correlate with poor prognosis in multiple tumor
types. We performed mRNA expression proﬁling in HCT116 cells over-expressing either p16 or p27 and
identiﬁed their regulatory genes. In silico transcription factor prediction indicated that most of the genes
speciﬁcally down-regulated by p27 are controlled by NF-Y. Under the hypothesis that NF-Y-targeted genes are
responsible for poor prognosis, we predicted prognosis in four types of cancer based on genes with the NF-Y
motif, and found a signiﬁcant association between the expression of NF-Y-targeted genes and poor prognosis.
© 2009 Elsevier Inc. All rights reserved.IntroductionCell cycle control is a highly coordinated process mediated by a
diversity of genes and proteins. Cyclin-dependent kinases (CDKs) play
a pivotal role in regulating the initiation and transition of cell cycle
phases by inactivating phosphorylation of the retinoblastoma (RB)
family of proteins, which leads to activation of the E2F transcription
factors [1]. The E2F transcription factors cooperating with DP1/2 to
sequentially transactivate the genes required for each phase of cell
cycle progression [2]. While CDKs are positively regulated by several
types of cyclins, their negative regulation is mediated by the CDK
inhibitors (CDKIs), which are divided into two classes; the INK4 and
CIP/KIP families based on their CDK inhibition spectrum [3]. Given the
fundamental functions of the CDK/RB/E2F pathway in cell cycle
control, deregulation of the components in this pathway, including
genetic/epigenetic alterations, over-expression and post-translational
aberrations, is a critical step in multistage carcinogenesis.
An INK4 family CDKI, CDKN2A (p16), binds to and inactivates CDK4
and CDK6 by inhibiting the association between these CDKs and D-type
cyclins. The p16-mediated inhibition of D-type cyclins controls early G1
cell cycle progression [4]. Although other INK4 family proteins such as
p15 (CDKN2B) and p18 (CDKN2C) show similar biological features inarch, Banyu Tsukuba Research
0-2611, Japan. Fax:+8129 877
ani).
ll rights reserved.vitro, the frequency of deregulation of p16 in tumors is signiﬁcantly
higher [5]. A 5′-CpG island in the promoter region of the p16 gene is
hypermethylated in various types of cancers including non-small cell
lung cancer (NSCLC), breast cancer and hepatocarcinoma (HCC) [6]. The
status of hypermethylation correlates with the p16 protein level when
measuredby immunohistochemistry in clinical samples. For example, in
one study of NSCLC, ∼26% of 27 tumor samples examined showed
hypermethylation in the promoter region of p16, leading to the down-
regulation of p16 mRNA expression [7]. The observation of mutual
inactivation of p16 andRB inNSCLC and SCLC alsopoints to an important
role for p16 in carcinogenesis as a tumor suppressor gene [8].
CDKN1B (p27) is a CIP/KIP family CDKI that binds to and regulates
CDK2, 4 and 6. Upon UV irradiation or cell contact inhibition, the
activated p27 inhibits D-type cyclins and CDKs, which arrests the cell
cycle at the G1 phase. p27 reduction is also required for completion of
the G1 phase and initiation of the S phase by sequential activation of
E-type and A-type cyclin and CDK2 complexes. The activated CDK2
up-regulates transcription of genes which participate in DNA synth-
esis and subsequent processes that occur at S phase [9]. With respect
to the association between p27 deregulation and cancer, p27 is
frequently inactivated in various types of cancers, which implies a
tumor suppressive function of the protein similar to p16. Unlike
classical tumor suppressors such as p53 (TP53) and RB (RB1), genetic
deletions or mutations of p27 are not frequently observed. However,
multiple reports have demonstrated that the protein expression level
of p27 is decreased or silenced in various types of cancers such as
breast, colon, and lung cancer [10]. The mechanism of the decreased
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SKP2, which is the ubiquitin ligase E3 of p27, is one of the causative
events of the decrease in p27 protein [11]. Despite detailed analysis of
p27 from the perspective of its inhibition spectrum of CDKs and its
post-translational regulation, p27-regulatory mRNA gene expression
as an end point of the p27/CDK/RB pathway remains elusive.
Although both p27 and p16 are inactivated at high frequency in
many types of cancers, and possess a common function involving
down-regulation of E2F regulatory genes via activation of RB proteins,
the impact of their expression levels on clinical prognosis differs [12].
p27 is widely regarded as an adverse prognostic indicator in a number
of tumor types, while p16 seems not to be an independent risk factor.
In a colon cancer study, the survival rate was poorer in p27-negative
tumors (median, 69 months) compared with p27 positive tumors
(median, 151 months), and p27 was an independent prognostic
marker [13]. In HCC, p27 acts as an independent predictor of HCC
recurrence among several cell cycle regulators such as RB, p21
(CDKN1A), cyclin D1 and p16 [14]. Breast cancer is one of the most
extensively studied tumor types with respect to the relationship
between p27 and prognosis. Reduced overall survival correlated
signiﬁcantly with down-regulation of p27 expression in a retro-
spective analysis with more than 2000 samples [15]. In contrast,
limited studies have shown the implications of p16 as a prognostic
predictor, although both p16 and p27 exhibit an inhibitory effect on
cell cycle progression via reducing E2F target genes. The molecular
mechanism bywhich p27 plays a distinct role fromp16 as a prognostic
factor remains elusive.
To date, a number of DNA microarray studies have clearly shown
their effectiveness in analyzing the molecular mechanisms at work in
the CDK/RB/E2F pathway. mRNA expression proﬁling of cultured cells
with over-expression of exogenous E2F enabled identiﬁcation of novel
E2F regulatory genes [16–23]. Microarray analysis of U2OS cells withFig. 1. Expression levels of p16 and p27, and cell cycle distribution post adenoviral infecti
carcinoma HCT116 cells were infected with p16-, p27- or control lacZ-expressing adenovirus
and shown as relative expression level to control. (b) Protein expression of p16 and p27.
infection, whole cell lysates were subjected toWestern blotting against anti-p16, anti-p27 or
described in b were labeled with propidium iodide to determine the DNA content, and cellectopic p16 expression or constitutively active RB expression has also
led to the identiﬁcation of p16/RB regulatory genes [24]. We have also
performed molecular proﬁling of RB positive and negative matched
pair cell lines, which resulted in the identiﬁcation of ECT2 as a novel
E2F regulatory gene [25]. These studies have demonstrated that global
expression proﬁling is a powerful approach to decipher the CDK/RB/
E2F pathway.
In the present study, we performedmicroarray analysis of cultured
cells over-expressing either p27 or p16 in order to investigate their
common and distinct features. While E2F-target genes were enriched
among the genes that were commonly changed by both CDKIs,
signiﬁcant enrichment of NF-Y-target genes was unexpectedly
observed in the gene set speciﬁcally down-regulated by p27
expression. The prediction of prognosis using the NF-Y-target genes
indicated that samples with up-regulated expression of the NF-Y-
target genes regulated by p27 showed poor prognosis in multiple
cancers, which could explain the molecular mechanism underlying
the distinct features of p27 and p16 as prognostic factors.
Results
Identiﬁcation of the genes commonly regulated by both p16 and p27
induction
To identify p16 and p27 target genes by microarray analysis,
human colorectal HCT116 cells were infected with adenovirus
expression vectors containing p16, p27, or the control lacZ gene at a
titer of 200 multiplicity of infection (moi). Before analysis, expression
levels of the CDK inhibitors in the cells were conﬁrmed with RT-PCR
and Western blotting. Similar expression levels were observed for
bothmRNA and protein of p16 and p27 (Fig.1a and b). Cell growthwas
arrested in both cells expressing p16 and p27. Cell cycle distributionon containing p16 and p27. (a) mRNA expression level of p16 and p27. Human colon
. Expression level of p16 and p27 mRNA was measured by quantitative RT-PCR analysis
HCT116 cells were infected with p16-, p27- or lacZ-expressing adenovirus. After 72 h
anti-β-actin antibodies. (c) Cell cycle distribution and subG1 induction. Cells treated as
cycle distribution of the stained cells was analyzed by ﬂow cytometry.
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increase in subG1 fraction was observed in cells expressing the CDK
inhibitors, exogenously introduced p16 and p27 were conﬁrmed to be
functional in HCT116 cells.
To elucidate the common and distinctive molecular functions
between p16 and p27, we carried out mRNA expression proﬁling of the
HCT116 cells over-expressing either p16 or p27 protein. At 24, 36, 48
and 72 h post infection, RNA was extracted from the cells and
subjected to mRNA expression proﬁling using the Affymetrix
oligonucleotide microarray, human GeneChip HG-U95Av2.
To determine the conserved similar roles between p16 and p27, we
selected genes whose expression was commonly up- or down-
regulated by both of the CDKIs. By comparing the expression proﬁles
of the HCT116 cells over-expressing p16 or p27 and control LacZ, we
extracted the genes which showed signiﬁcant (P≤1.0×10−5)
expression changes in at least one of the time points (24, 36, 48 or
72 h) in both of the cells over-expressing p16 and p27. Elimination of
genes with a small range of expression change was also performed as
described in Materials and methods. Using the described criteria, 62
and 5 probes were extracted as down- and up-regulated genes
respectively. In Fig. 2, shows the hierarchical clustering of the selected
genes, verifying the conserved regulation of the clustered genes by
both of the CDKIs. To examine the relationship between the selected
genes and cell cycle phases, the genes known to be tightly regulated at
each phase of S, G1/S, G2, G2/M and M/G1 were annotated for the
commonly regulated genes (Fig. 2 right panel). The annotation was
based on previous studies conducted by Whitﬁeld et al. which
comprehensively investigated cell cycle related genes by performing
mRNA expression proﬁling of HeLa cells in which the cell cycles hadFig. 2. Expression proﬁle of the genes down-/up-regulated in both p16 and p27 over-
expressed cell lines. Each gene is represented by a single row of colored boxes, and each
experimental condition is represented by a single column (from left to right: p16 over-
expression at 24, 36, 48 and 72 h, and p27 over-expression at 24, 36, 48 and 72 h). A
visual dual color code is utilized with red and green indicating relatively high and low
ratios, respectively. The scale of color saturation, which reﬂects the ratios, is shown
below. The panel at the right side of the heatmap shows the relationship between the
clustered genes and cell cycle phases. A red square indicates that the gene is up-
regulated at the cell cycle phase; S, G1/S, G2, G2/M andM/G1. The relationship is based
on previous studies conducted by Whitﬁeld et al. which comprehensively investigated
periodically expressed genes in synchronized cells.
Fig. 3. Expression proﬁles of the genes speciﬁcally down-/up-regulated in p16 or p27
over-expressed cell lines. (a) Expression proﬁle of the genes up-/down-regulated by
p27 but not by p16. (b) Expression proﬁle of the genes up-/down-regulated by p16 but
not by p27. The scale of color saturation, which reﬂects the ratios, is shown below.
Relationships between each gene and each cell cycle phase are denoted in the same
fashion as those in Fig. 2.been synchronized [26]. As the ﬁgure shows, time course-dependent
cell cycle related gene expression changes were induced by the CDKIs.
Down-regulation of G1/S related genes was observed at 24 h followed
by down-regulation of the G2/M related genes at 36 to 48 h, which
conﬁrmed that both CDKIs prevent cell cycle progression via the CDK/
RB/E2F pathway.
Identiﬁcation of the genes whose expression is speciﬁcally regulated by
p16 or p27
In addition to the common features of the two inhibitors, distinct
functions of p16 and p27 have also been reported, and include the
example of different inhibitory partners of CDKs by the CDKIs. Next, to
investigate the speciﬁc roles of each of the two CDKIs, we selected
genes whose expression was selectively changed by the exogenous
over-expression of each CDK inhibitor. The speciﬁcally regulated
genes were selected based on the following criteria: 1, genes which
showed more than 2.5-fold expression changes with statistical
signiﬁcance (P≤1.0×10−5) in at least one of the time points (24,
36, 48 or 72 h) in p27 over-expressed cell lines; and 2, genes which did
not show signiﬁcant expression changes at any of the time points by
the over-expression of p16. With respect to genes speciﬁcally
regulated by p16, for the most part the same criteria were utilized
Table 1a
Transcription factor binding motifs of TRANSFAC signiﬁcantly (P≤0.0001) enriched in
the promoter regions of each gene set.
Transcription factor Motif P value # of genes
E2F V$E2F_Q6 2.15E−07 30
E2F V$E2F_Q4_01 1.60E−06 15
E2F1 V$E2F1_Q6_01 2.51E−06 20
E2F1 V$E2F1_Q4_01 2.99E−06 15
E2F1 V$E2F1_Q6 3.00E−06 19
E2F V$E2F_Q3 6.09E−06 17
E2F V$E2F_Q3_01 6.86E−06 16
E2F1 V$E2F1DP2_01 1.89E−05 18
E2F V$E2F_Q6_01 1.93E−05 16
E2F V$E2F_Q4 3.43E−05 32
NF-Y V$NFY_01 6.94E−05 13
E2F4/DP2 V$E2F4DP2_01 9.65E−05 19
The listed transcription factor binding motifs of TRANSFAC were enriched among the
genes down-regulated in both p16 and p27 over-expressed cell lines. Transcription
factor binding sequence motifs for each TRANSFAC motif ID are shown in Supplemental
Fig. 1.
Fig. 4. NF-Y transcription factor binding motifs, and biological function enrichments
among the genes speciﬁcally regulated by p27 and having NF-Y promoter motifs. (a)
Sequence logo representation of the transcription factor binding motifs signiﬁcantly
enriched among the promoter region of the genes speciﬁcally down-regulated in p27
over-expressed cells. (b) The bar graph depicts− log10 (P value) as deﬁned inMaterials
and methods.
Table 2
Genes speciﬁcally regulated by p27 and having NF-Y binding promoter motifs.
Probe EntrezGene Symbol Gene name
34852_g_at
6790 AURKA Aurora kinase A34851_at
1544_at 641 BLM Bloom syndrome
33324_s_at 983 CDC2 Cell division cycle 2, G1 to S and G2 to M
1599_at 1033 CDKN3 Cyclin-dependent kinase inhibitor 3
37302_at 1063 CENPF Centromere protein F, 350/400ka
39337_at 3015 H2AFZ H2A histone family, member Z
442_at 7184 HSP90B1 Heat shock protein 90 kDa beta, (Grp94),
member 1
947_at 4176 MCM7 Minichromosome maintenance complex
component 7
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53 probes were shown to be speciﬁc p27 regulatory genes, of which 49
and 4 probes were decreased and increased, respectively, by the over-
expression of p27. Regarding p16 speciﬁc genes, 8 and 4 probes were
identiﬁed to be down- and up-regulated genes, respectively. Fig. 3
shows the hierarchical clustering of the genes speciﬁcally regulated by
p27 (Fig. 3a) and p16 (Fig. 3b) with annotation of cell cycle phases as
deﬁned in the analysis of commonly regulated genes. Different from
the result of commonly regulated genes, the G2/M related genes were
enriched among the p27 regulatory genes, suggesting additional
functions for p27 in the coordination of G2/M cell cycle progression
compared with p16. In contrast, no signiﬁcant relationship to any cell
cycle phase was observed among the p16 regulatory genes.
In silico identiﬁcation of the transcription factors participating in the
networks of p16 and p27
The downstream regulatory genes induced by p16 and p27 that
were identiﬁed in the current molecular proﬁling (Fig. 3) differed
markedly, which infers that p27 and p16 transduce signals to distinct
downstream transcription factors. Next, in order to identify the
transcription factors responsible for the differences in the mRNA
expression proﬁling between the p16 or p27 inductions, we searched
by in silico analysis for transcription factors that bind to the promoter
region of the commonly or speciﬁcally regulated genes. We analyzed
the promoter regions of six groups of genes: commonly up- or down-
regulated by both p16 and p27, speciﬁcally up- or down-regulated by
p27, and speciﬁcally up- or down-regulated by p16. The in silico
identiﬁcation of transcription factors was performed using the
TRANSFAC database (release 11.3, November 2007) [27] and over-
abundance of the identiﬁed binding sites among each gene set was
evaluated based on hypergeometric distribution. Consistent with
previous reports, E2F family transcription factor binding sites were
signiﬁcantly overabundant within the genes commonly down-
regulated in p16 and p27 over-expressed cells (Table 1a). In contrast,
NF-Y transcription factor binding sites were signiﬁcantly overabun-Table 1b
Transcription factor binding motifs of TRANSFAC signiﬁcantly (P≤0.0001) enriched in
the promoter regions of each gene set.
Transcription factor Motif P value # of genes
NF-Y V$CAAT_01 2.78E−05 13
NF-Y V$NFY_C 4.67E−05 15
NF-Y V$NFY_01 6.51E−05 11
List of the transcription factor binding motifs enriched among the genes speciﬁcally
down-regulated in p27 over-expressed cell lines but not in p16 over-expressed lines.
Enrichment P values were calculated using the hypergeometric distribution.dant among the genes speciﬁcally down-regulated by p27 but not by
p16 (Table 1b, Fig. 4a), indicating that the majority of the p27
regulatory genes were down-regulated by an NF-Y transcription factor
downstream of the p27/CDK cascade. In the analysis of the promoter
regions of the other gene sets, no signiﬁcant overabundance of any of
the speciﬁc transcription factor binding sites was observed (data not
shown). The genes speciﬁcally down-regulated by p27 induction that
contain an NF-Y binding motif in their promoter regions are listed in
Table 2, and an enrichment test for the genes was performed by gene
ontology biological process annotation (Fig. 4b). The results demon-
strated that statistically signiﬁcant overabundance of mitosis-related
genes was included in the NF-Y target genes speciﬁcally down-38847_at 9833 MELK Maternal embryonic leucine zipper kinase
33483_at 10874 NMU Neuromedin U
35643_at 4925 NUCB2 Nucleobindin 2
37228_at 5347 PLK1 Polo-like kinase 1
38589_i_at 5757 PTMA Prothymosin, alpha
38940_at 57405 SPC25 SPC25, NDC80 kinetochore complex
component, homolog
41400_at
7083 TK1 Thymidine kinase 1, soluble910_at
1592_at 7153 TOP2A Topoisomerase, (DNA) II alpha 170 kDa
39109_at 22974 TPX2 TPX2, microtubule-associated, homolog
The listed genes were speciﬁcally down-regulated in p27 over-expressed cell lines and
have NF-Y binding promoter motifs in their promoter region.
Fig. 5. NF-YA activity in HCT116 cells over-expressing p16 or p27. Nuclear extracts from
HCT116 infected with p16-, p27- or lacZ-expressing adenovirus were analyzed for the
binding ability to the NF-YA consensus binding site by an ELISA-based assay. ⁎Pb0.05,
and ⁎⁎Pb0.01 compared with the control.
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TOP2A, BLM, SPC25, and PTMA (P≤1.0×10−12) (Fig. 4b, Table 2),
which are known to regulate chromosome condensation, centrosome
regulation or sister chromatid separation [28]. This further supports
the idea that p27 negatively regulates a diverse array of mitotic events
through the NF-Y transcription factor.
Activation NF-YA (NFYA), a regulatory subunit of NF-Y, was
experimentally measured in HCT116 cells followed by p16 or p27
induction. Nuclear extracts from the HCT116 cells at 0, 24, 48 and 72 h
post CDK inhibitor induction was used to quantify the binding ability
of NF-YA to the oligonucleotide harboring the NF-YA consensus
binding site (5′-CCAAT-3′). While p16 induction did not change NF-YA
activity, p27 induction signiﬁcantly reduced the activity to 49%
compared with the control at 72 h post infection (Fig. 5).Fig. 6. Gene expression proﬁles and patient survival analysis. Kaplan–Meier plots showing
expression of the genes in Table 2 is negative; Type 2: tumors whose mean expression of the
right side of each Kaplan–Meier plot shows the expression proﬁle of the genes in each patient
(a) Breast, (b) lung, (c) multiple myeloma and (d) renal.Expression levels of the genes speciﬁcally regulated by p27 show
signiﬁcant correlation with tumor prognosis
One of the most remarkable clinical differences between p16 and
p27 is the association of tumor prognosis with the expression level of
the each CDK inhibitor. Multiple studies have suggested that reduced
p27 protein levels are associated with poor prognosis [10]; although
the information on the association with p16 is limited. We
hypothesized that the difference in the transcriptional control down-
stream of the two CDKIs, in particular the NF-Y-target genes in the p27
gene signature, would be one of the determinants responsible for the
prognosis difference between the two CDKIs. To examine this
hypothesis, we checked the correlation between the expression
proﬁles of the 17 genes in Table 2 and tumor prognoses. We collected
publicly available microarray data of four types of tumors with patient
survival information (Breast, van de Vijver et al. [29]; lung,
Bhattacharjee et al. [30]; multiple myeloma, Carrasco et al. [31,32];
Renal, Yang et al. [33]), normalized the data (as detailed in Materials
and methods), and calculated the average expression values of the
genes in Table 2. Based on the calculated values, patients were divided
into two groups. The poor prognosis group (mean expression levels
≥0) and the good prognosis group (mean expressions b0). For each
tumor type, overall survival probabilities between the two groups
were compared using Kaplan–Meier analysis and the log–rank test
and it was found that the tumor prognoses were signiﬁcantly different
between the two groups in all the four tumors (Fig. 6). In breast
cancer, for instance, in which 167 and 128 patients were classiﬁed
as having good and poor prognosis respectively, the survival prob-
abilities were signiﬁcantly different between the two groups,
(P=2.3×10−10) (Fig. 6a). Similarly, the expression levels of the NF-
Y-target genes in the p27 gene signature were associated with good
and poor prognosis in the lung cancer, multiple myeloma and renal
cancer patients. On the other hand, when tumors were divided by thesurvival rates of type 1 (red) and type 2 (blue) patients. Type 1: tumors whose mean
set of genes is positive. P values were calculated by the log–rank test. The heatmap at the
. Borderline classiﬁcation of the patients into type 1 and type 2 is denoted by awhite line.
Table 3
Correlation between expression levels of each signature and tumor prognosis.
Down-regulated
only in p27
Down-regulated
only in p16
Genes in Table 2
Breast 1.8×10−8⁎⁎ 0.081 2.3×10−10⁎⁎
Lung 0.061 0.39 0.042⁎
Multiple myeloma 0.0062⁎⁎ 0.17 0.0062⁎⁎
Renal 0.048⁎ 0.37 0.038⁎
This table shows the relationship between patient survival and the expression level of
each set of genes. P values were calculated using the log–rank test, when breast, lung,
multiple myeloma and renal cancer patients were classiﬁed into two groups based on
the expression level of each set of genes. When patients were classiﬁed based on
expression level of the genes in Table 2, the patient survival rate showed the most
signiﬁcant difference for each tumor.
Fig. 7. Probable regulatory network of p16 and p27. E2F family transcription factor
activity is inhibited by both p16 and p27 through the inhibition of CDK4 and CDK2. On
the other hand, NF-Y activity is modulated by CDK2, and p27 affects on NF-Y
transcriptional activity, whereas p16 does not. When we checked the correlation
between the expression proﬁle of the genes and tumor prognosis, the NF-Y regulatory
genes showed the most signiﬁcant correlations. NF-Y regulation through CDK2 may
explainwhy decreased p27 levels are linked to poor outcome in several types of tumors.
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signiﬁcant differences were not observed between the two groups for
any type of tumor (Table 3). When the prognosis was predicted by the
genes down-regulated by p27, a prognosis difference was observed
between the two groups, but with a lesser difference compared with
that predicted by the NF-Y-target genes (Table 3).
Discussion
This analysis of expression proﬁling has shown that E2F target
genes were enriched in the commonly regulated genes by p16 and
p27, providing conﬁrmation of the function of CDKI in repressing E2F
regulatory genes. While p16 exerts its inhibitory activity on cell cycle
progression by binding to CDK4/6, p27 is known to form complexes
with CDK2 in addition to CDK4/6. The inhibition of CDK2 or CDK4/6
prevents phosphorylation of RB as a conserved characteristic of all the
CDKs, bestowing docking sites on E2F transcription factors that lead to
down-regulation in their regulatory genes. Consistent with the
present study, a number of reports have illustrated that over-
expression of CDKIs down-regulates E2F regulatory genes such as
CCNA2, CCNB1 and PCNA, although global expression proﬁling
comparing p16 and p27 has not been reported [24,34–37]. Enrichment
of the E2F regulatory genes in the common gene signature induced by
p16 and p27 ensures that the experimental design and thresholds
were reasonable in order to identify commonly and speciﬁcally
regulated genes by p16 and p27.
The analysis of the p27 speciﬁc genes using the hypergeometric
distribution test and the in silico promoter search suggested that the
suppression of the NF-Y-target genes that coordinate G2/M cell cycle
transition is a distinct feature of p27 compared with p16. p27 is well
known to form complexeswith CDK2 in addition to CDK4/6 in G1/S cell
cycle transition. Previously, CDK2 has been reported to phosphorylate
NF-Y transcription factor as one of the primary substrates in cancer cells
in response to mitotic stimuli, which leads to an increase in its
transactivation ability [38]. The importance of NF-Y in G2/M cell cycle
transition under the control of CDK2 has been demonstrated in both in
vitro and in vivo studies [39]. Given the relationship between p27 and
CDK2, and CDK2 and NF-Y, the novel ﬁnding in the present study that
p27 over-expression down-regulates NF-Y-target genes might be
explained by the following sequential events: p27 induction in HCT116
inactivates CDK2 kinase activity and the resulting hypophosphorylated
NF-Y thus reduces expression of its target genes. As this mechanism is
based on results obtainedwithHCT116 cells, its applicability to other cell
lines is limited. Some genes included in Table 2 have already been
reported to be regulated by p16 in U-2 OS cells [24]. Further studies are
needed in other types of cell lines to conﬁrm thismechanism.Moreover,
further validation studies examining the regulation of the genes in
Table 2 by NF-Y both in vitro and in vivo, in addition to the present in
silico analysis, would strengthen our argument.
The expression of p27 is associated with poor prognosis in a variety
of tumor types. In hormone receptor positive breast cancer, for instance,
lower expression of p27 was correlated with both lower overall survivaland lower disease free survival, while no prognostic association was
observed for CyclinE which was examined as a downstream effecter for
p27 [15]. Another study on lung cancer also showed that deregulated
expression of p27 is a strong indicator for poor patient prognosis, in
contrast to the ﬁnding that the p16 expression level did not exhibit any
correlationwith prognosis, highlighting the useful role of p27 to predict
patient prognosis [40]. Despite the various reports indicating the role of
the expression level of p27 as a prognostic factor, the molecular
mechanism explaining why p27 expression determines the prognosis
has remained unknown. The present study found that NF-Y-target genes
speciﬁcally regulated by p27 correlated with poor prognosis in multiple
tumors such as breast, lung, renal cancers and multiple myeloma.
Although p27 controls the expression levels of both E2F- and NF-Y-
target genes downstream of the CDKI/CDK cascade, the expression
changes in the genes regulated by the NF-Y transcription factor would
associate with clinical prognosis. Indeed, many oncogenic proteins such
as MELK, Aurora kinase, and TPX2 were included in the NF-Y-target
genes (Table 2) which are known to modulate a diverse range of phases
of the G2/M cell cycle [41,42]. The NF-Y-target genes may enhance
cancer progression by accelerating G2/M phase cell cycle transition,
leading to poor patient prognosis.
In summary, we have identiﬁed the speciﬁc role of p27 compared
with p16 to regulate NF-Y-target genes as an end point in its
downstream cascade. The common and speciﬁc functions predicted
through the analysis of the expression proﬁle are depicted in Fig. 7.
Moreover, the importance of the NF-Y-target genes regulated by p27
induction has beenproposed by associating theNF-Y-target geneswith
patient prognosis in several types of tumors. This global expression
analysis has provided some insights into the speciﬁc function of p27
and its relevance to cancer prognosis, and may explain how p27 is
associated with prognosis in various types of cancer compared with
p16, despite both CDKIs being aberrantlyexpressed inmultiple tumors.
Materials and methods
Quantitative RT-PCR assay
Human colon carcinoma HCT116 cells were infected with p16-,
p27- or lacZ-expressing adenovirus (200 moi). cDNAwas synthesized
225K. Yamanaka et al. / Genomics 94 (2009) 219–227from 1 μg total RNA using TaqMan reverse transcription reagents
(#N8080234, Applied Biosystems). Quantitative real-time PCR was
performed for human p16, p27 and β-actin in triplicate for cDNA
samples in 96-well optical plates. Data were collected and analyzed
using an ABI PRISM 7900 sequence detector system (Applied
Biosystems). Commercially available pre-designed primers and
probe for RT-PCR were used: p16 (Hs00233365_m1, Applied Biosys-
tems); p27 (Hs00153277_m1, Applied Biosystems); β-actin
(4310881E, Applied Biosystems).
Western blotting
HCT116 cells were infected with p16-, p27- or lacZ-expressing
adenovirus. After 72 h infection, equal amounts of protein were
extracted and resolved on NuPAGE 4–12% Bis-Tris polyacrylamide gels
(Invitrogen, Carlsbad, CA) and then electrophoretically transferred
onto PVDF membranes (Millipore, Billerica, MA). Membranes were
incubated with anti-p16 (sc-1005, Santa Cruz Biotechnology, CA),
anti-p27 (sc-1005, Santa Cruz Biotechnology) or anti-β actin (sc-1005,
Santa Cruz Biotechnology) antibodies, followed by HRP-conjugated
secondary antibody. Antibody binding was detected using the ECL
system (GE Healthcare, Piscataway, NJ).
Flow cytometry
Using the treated HCT116 cells prepared as described for Western
blotting, following 72 h infection, cells were stained using Cycle TEST™
PLUS DNA Reagent Kit (Becton Dickinson, Franklin Lakes, NJ) and
analyzed by ﬂow cytometry with FACSCalibur (BD Biosciences, CA).
Microarray analysis with Affymetrix GeneChips
Affymetrix human GeneChips HG-U95Av2 (Affymetrix, Santa
Clara, CA) were used in all experiments. The samples for Affymetrix
DNA microarray analysis were prepared as described by the
manufacturer. An initial analysis of the data generated from the
microarray images focused on simple determinations of fold changes
within the comparisons of lacZ containing virus vector infected
HCT116 cell samples versus p16 or p27 containing virus vector
infected HCT116 cell samples, at each time point (24, 36, 48 and 72 h).
Data analysis was performed using Resolver software (Rosetta Biosoft,
Seattle, WA). In the Resolver system, intensity proﬁles were calculated
with Affymetrix APT RMA algorithm. The intensity proﬁles generated
were used to build ratios using Rosetta Resolver Ratio Builder for
calculating the fold change and its P values for the differential
expression between p16/p27- and lacZ-over-expressing cells. The
criterion for a signiﬁcant change in expression was P≤0.00001. The P
values were statistically signiﬁcant (P≤0.05) when multiplicity
corrected P values were calculated with Benjamini-Hochberg FDR.
To identify genes whose expression was regulated by both p16 and
p27, we ﬁrst extracted the genes which showed signiﬁcant expression
changes in at least one of the time points in both of the cells over-
expressing p16 and p27. Next, to ﬁlter out genes with a small range of
expression change, genes were eliminated if more than 1.5-fold and
2.5-fold changes were not observed in p16 and p27 over-expressed
cell lines, respectively. The fold-change thresholds were determined
based on the changes in expression of major E2F regulatory genes; as
shown in Supplementary Fig. 2, the average change in expression of
the E2F regulatory genes induced by p16 and p27 were 1.6- and 2.2-
fold at 24 h post infection, respectively. When genes were speciﬁcally
regulated by p16 and not by p27, we selected the genes which showed
more than 1.5-fold expression changes with statistical signiﬁcance in
at least one of the time points in p16 over-expressed cell lines but no
signiﬁcant expression change in any of the time points by the p27
over-expression. For the genes speciﬁcally regulated by p27, for the
most part the same criteria were utilized, except that a 2.5-fold-change threshold was applied. To produce the hierarchical clustering
of each gene set, MATLAB software (The Mathworks, Natick, MA) was
used to perform the calculation and to display the results graphically.
Cosine correlation was applied to calculate gene distances and a
hierarchical tree was created based on average linkage. For all
calculations the log ratio was used.
Transcription factor prediction
The transcription factor binding site matrices were obtained from
version 11.3 of TRANSFAC® Professional [27], and using only high
quality matrices for the vertebrate group. To search for putative
transcription factor binding sites in DNA sequences with these
matrices, we used Match™ with a cut-off of minimizing false positive
rate (minFP) [43]. The promoter region of each gene was generated
through the following procedure. We obtained the “upstream1000.
zip”, “refMrna.zip” and “refSeqAli.txt.gz” ﬁles from the University of
California Santa Cruz genome browser (http://genome.ucsc.edu,
assembly released on March 2006, version hg18) [44]. Depending
on the alignment information of each gene in refSeqAli.txt.gz, and
using refMrna.zip and upstream1000.zip, we produced promoter
sequences that included 1000 bp of upstream sequence from the start
site of each Reference Sequence (RefSeq) [45] and the exon 1
sequences of each RefSeq. If the length of the exon 1 sequence was
over 200 bp, we used only 200 bp of exon 1 and cut off the extra
nucleotides. The correspondence of each gene on the GeneChip to the
RefSeq ID was determined according to NetAffx [46]. The promoter
sequences of 8321 genes could be speciﬁed among the 10500 genes on
the GeneChip. To identify statistically overabundant transcription
factors for the promoter region of the co-regulated group of genes, we
calculated the P values using the hypergeometric distribution
function:
P value = 1−
Xx−1
i=0
K
i
 
M − K
N − i
 
M
N
  ð1Þ
whereN is the total number of the genes in a given set of signatures, x is
the number of genes that have a promoter sequence predicted to have a
binding site for the transcription factor among the signature genes, K is
the number of genes having promoter sequences which have binding
motifs of the transcription factor, and M is the total number of genes in
the control promoter sequences (in this studyMwas set to 8321).
Enrichment test
According to NetAffx and the BIOBASE's Proteome BioKnowledge
Library (HumanPSD™) from Incyte Corporation (Incyte, Wilmington,
DE) [47], we annotated each gene with Gene Ontology (GO) biological
process terms [48]. To determine whether the GO terms associated
with particular biological processes were over-represented among the
genes in each gene set, we calculated the P values using the
hypergeometric distribution function. The function to calculate the P
values was the same as function (1), where N was the number of
genes in a given set, x was the observed number of genes found in
both a given set of genes and a given functional category, K was the
number of the genes in a given functional category, and M was the
total number of the genes represented on themicroarray (in this study
M was set to 8601).
NF-YA activity assay
HCT116 cells were infected with p16-, p27- or lacZ-expressing
adenovirus. At 0, 24, 48 and 72 h post infection, nuclear extract from
the HCT116 cells were recovered with Nuclear Extract Kit (Active
Motif, CA). The NF-YA activity in the nuclear extracts were measured
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Brieﬂy, 3 μg of nuclear extracts were incubated with the oligonucleo-
tide containing the NF-YA consensus binding site which was
immobilized on a 96-well plate. NY-FA antibody was added and
incubated for 1 h followed by an additional 1-h incubation with anti-
IgG HRP conjugate. Then, the NF-FY activity was quantiﬁed by
spectrophotometry.
Public microarray data for primary tumors
Four data sets were downloaded from the GEO database
(http://www.ncbi.nlm.nih.gov, GSE4452 for multiple myeloma
[31,32] and GSE2748 for renal cancer [33]) and from the authors'
individual web pages (Rosetta Inpharmatics web site: http://www.
rii.com/publications/2002/nejm.html for breast cancer [29] and
Broad Institute of MIT web sites: http://www.genome.wi.mit.edu/
cgi-bin/cancer/publications/pub_menu.cgi for lung cancer [30]).
These data sets included both single-channel Affymetrix (lung,
multiple myeloma and renal) and dual-channel oligonucleotides
(breast) array data. The dual-channel microarray data of breast cancer
shows ratio values of each tumor versus pooled tumors for each gene.
In contrast, the single-channel data shows intensity values of each
tumor for each gene. In order to analyze these data in the same
fashion, we preprocessed the intensity based microarray data and
calculated the ratio expression values for each gene against the
averaged intensity value of all tumors in each data set. The normal-
ization step was as follows: signal intensities were log transformed,
and average values were calculated for each gene with all tumor
samples. By subtracting the averaged values from the intensities of
each sample, the log ratio values were calculated. When log
transformation was applied, we used log10 transformation for MAS5
based intensities and log2 transformation for RMA based intensities.
Correlation of the microarray data with tumor prognosis
All of the collected primary tumor datasets also have survival time
parameters for the patients. To check the correlation between the
expression proﬁle of a given set of genes and tumor prognosis, the
data was analyzed using Kaplan–Meier curves and the log–rank test.
In each microarray dataset of a primary tumor, once a gene set was
given, the average expression value of the genes was calculated for
each tumor and the tumors were divided into two groups based on
whether the valuewas positive or negative. After classifying the tumor
samples, the log–rank test was applied to infer the statistical
signiﬁcance of differences in survival time between the two groups,
and a Kaplan–Meier plot was also used to show the differences in
survival. All the calculations were performed using MATLAB software
(The Mathworks).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2009.06.003.
References
[1] C.J. Sherr, The Pezcoller lecture: cancer cell cycles revisited, Cancer Res. 60 (2000)
3689–3695.
[2] J.M. Trimarchi, J.A. Lees, Sibling rivalry in the E2F family, Nat. Rev. Mol. Cell Biol. 3
(2002) 11–20.
[3] C.J. Sherr, J.M. Roverts, CDK inhibitors: positive and negative regulators of
G1-phase progression, Genes Dev. 13 (1999) 1501–1512.
[4] M.F. Roussel, The INK4 family of cell cycle inhibitors in cancer, Oncogene 18 (1999)
5311–5317.
[5] J. Tsihlias, L. Kapusta, J. Slingerland, The prognostic signiﬁcance of altered cyclin-
dependent kinase inhibitors in human cancer, Annu. Rev. Med. 50 (1999)
401–423.
[6] M. Esteller, P.G. Corn, S.B. Baylin, J.G. Herman, A gene hypermethylation proﬁle of
human cancer, Cancer Res. 61 (2001) 3225–3229.[7] A. Merlo, et al., 5′ CpG island methylation is associated with transcriptional
silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers, Nat.
Med. 1 (1995) 686–692.
[8] G.I. Shapiro, et al., Reciprocal Rb inactivation and p16INK4 expression in primary
lung cancers and cell lines, Cancer Res. 55 (1995) 505–509.
[9] A. Besson, S.F. Dowdy, J.M. Roberts, CDK inhibitors: cell cycle regulators and
beyond, Dev. Cell 14 (2008) 159–169.
[10] I.M. Chu, L. Hengst, J.M. Slingerland, The Cdk inhibitor p27 in human cancer:
prognostic potential and relevance to anticancer therapy, Nat. Rev. Cancer 8
(2008) 253–267.
[11] K.I. Nakayama, K. Nakayama, Ubiquitin ligases: cell-cycle control and cancer, Nat.
Rev. Cancer 6 (2006) 369–381.
[12] M. Malumbres, M. Barbacid, To cycle or not to cycle: a critical decision in cancer,
Nat. Rev. Cancer 1 (2001) 222–231.
[13] M. Loda, et al., Increased proteasome-dependent degradation of the cyclin-
dependent kinase inhibitor p27 in aggressive colorectal carcinomas, Nat. Med. 3
(1997) 231–234.
[14] Y. Ito, et al., Expression and prognostic roles of the G1-S modulators in
hepatocellular carcinoma: p27 independently predicts the recurrence, Hepatol-
ogy 30 (1999) 90–99.
[15] P.L. Porter, et al., p27(Kip1) and cyclin E expression and breast cancer survival
after treatment with adjuvant chemotherapy, J. Natl. Cancer Inst. 98 (2006)
1723–1731.
[16] H. Müller, et al., E2Fs regulate the expression of genes involved in differentiation,
development, proliferation, and apoptosis, Genes Dev. 15 (2001) 267–285.
[17] S. Ishida, et al., Role for E2F in control of both DNA replication and mitotic
functions as revealed from DNA microarray analysis, Mol. Cell. Biol. 21 (2001)
4684–4699.
[18] B. Ren, et al., E2F integrates cell cycle progressionwith DNA repair, replication, and
G2/M checkpoints, Genes Dev. 16 (2002) 245–256.
[19] S. Polager, Y. Kalma, E. Berkovich, D. Ginsberg, E2Fs up-regulate expression of
genes involved in DNA replication, DNA repair and mitosis, Oncogene 21 (2002)
437–446.
[20] A.S. Weinmann, P.S. Yan, M.J. Oberley, T.H. Huang, P.J. Farnham, Isolating human
transcription factor targets by coupling chromatin immunoprecipitation analysis,
Genes Dev. 16 (2002) 235–244.
[21] M.P. Markey, et al., Unbiased analysis of RB-mediated transcriptional repression
identiﬁes novel targets and distinctions from E2F action, Cancer Res. 62 (2002)
6587–6597.
[22] J. Wells, P.S. Yan, M. Cechvala, T. Huang, P.J. Farnham, Identiﬁcation of novel pRb
binding sites using CpG microarrays suggests that E2F recruits pRb to speciﬁc
genomic sites during S phase, Oncogene 22 (2003) 1445–1460.
[23] A.P. Young, R. Nagarajan, G.D. Longmore,Mechanisms of transcriptional regulation
by Rb-E2F segregate by biological pathway, Oncogene 22 (2003) 7209–7217.
[24] R. Vernell, K. Helin, H. Müller, Identiﬁcation of target genes of the p16INK4A-pRB-
E2F pathway, J. Biol. Chem. 278 (2003) 46124–46137.
[25] T. Eguchi, T. Takaki, H. Itadani, H. Kotani, RB silencing compromises the DNA
damage-induced G2/M checkpoint and causes deregulated expression of the
ECT2 oncogene, Oncogene 26 (2007) 509–520.
[26] M.L. Whitﬁeld, et al., Identiﬁcation of genes periodically expressed in the human
cell cycle and their expression in tumors, Mol. Biol. Cell 13 (2002) 1977–2000.
[27] V. Matys, et al., TRANSFAC: transcriptional regulation, from patterns to proﬁles,
Nucleic Acids Res. 31 (2003) 374–378.
[28] I. Pérez de Castro, G. de Cárcer, M. Malumbres, A census of mitotic cancer genes:
new insights into tumor cell biology and cacer therapy, Carcinogenesis 28 (2007)
899–912.
[29] M.J. van de Vijver, et al., A gene-expression signature as a predictor of survival in
breast cancer, New Engl. J. Med. 347 (2002) 1999–2009.
[30] A. Bhattacharjee, et al., Classiﬁcation of human lung carcinomas by mRNA
expression proﬁling reveals distinct adenocarcinoma subclasses, Proc. Natl. Acad.
Sci. U. S. A. 98 (2001) 13790–13795.
[31] D.R. Carrasco, et al., High-resolution genomic proﬁles deﬁne distinct clinico-
pathogenetic subgroups of multiple myeloma patients, Cancer Cell 9 (2006)
313–325.
[32] K. Sukhdeo, et al., Targeting the beta-catenin/TCF transcriptional complex in the
treatment ofmultiplemyeloma, Proc. Natl. Acad. Sci. U. S. A.104 (2007) 7516–7521.
[33] X.J. Yang, et al., A molecular classiﬁcation of papillary renal cell carcinoma, Cancer
Res. 65 (2005) 5628–5637.
[34] J. Mitra, et al., Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by
the tumor suppressor p16(INK4a), Mol. Cell. Biol. 19 (1999) 3916–3928.
[35] M. Kim, et al., Induction of apoptosis in p16INK4a mutant cell lines by adenovirus-
mediated overexpression of p16INK4A protein, Cell Death Differ. 7 (2000) 706–711.
[36] P. Shiyanov, et al., p27Kip1 induces an accumulation of the repressor complexes of
E2F and inhibits expression of the E2F-regulated genes, Mol. Biol. Cell 8 (1997)
1815–1827.
[37] Y.H. Kwon, A. Jovanovic, M.S. Serfas, H. Kiyokawa, A.L. Tyner, p21 functions to
maintain quiescence of p27-deﬁcient hepatocytes, J. Biol. Chem. 277 (2002)
41417–41422.
[38] H.D. Chae, J. Yun, Y.J. Bang, D.Y. Shin, Cdk2-dependent phosphorylation of the NF-Y
transcription factor is G1/S and G2/M transitions, Oncogene 23 (2004) 4084–4088.
[39] J. Yun, et al., Cdk2-dependent phosphorylation of the NF-Y transcription factor and
its involvement in the p53-p21 signaling pathway, J. Biol. Chem. 278 (2003)
36966–36972.
[40] H. Hirabayashi, et al., Prognostic signiﬁcance of p27KIP1 expression in resected
non-small cell lung cancers: analysis in combination with expressions of
p16INK4A, pRB, and p53, J. Surg. Oncol. 81 (2002) 177–184.
227K. Yamanaka et al. / Genomics 94 (2009) 219–227[41] D.M. Glover, Aurora A on the mitotic spindle is activated by the way its holds its
partner, Mol. Cell 12 (2003) 797–799.
[42] N. Davezac, V. Baldin, J. Blot, B. Ducommun, J.P. Tassan, Human pEg3
kinase associates with and phosphorylates CDC25B phosphatase: a
potential role for pEg3 in cell cycle regulation, Oncogene 21 (2002)
7630–7641.
[43] A.E. Kel, et al., MATCH: a tool for searching transcription factor binding sites in
DNA sequences, Nucleic Acids Res. 31 (2003) 3576–3579.
[44] D. Karolchik, et al., The UCSC Genome Browser Database: 2008 update, Nucleic
Acid Res. 36 (2008) D773–779.[45] K.D. Pruitt, T. Tatusova, D.R. Maglott, NCBI reference sequences (RefSeq): a curated
non-redundant sequence database of genomes, transcripts and proteins, Nucleic
Acids Res. 35 (2007) D61–65.
[46] G. Liu, et al., NetAffx: Affymetrix probesets and annotations, Nucleic Acids Res. 31
(2003) 82–86.
[47] P.E. Hodges, et al., Annotating the human proteome: the Human Proteome Survey
Database (HumanPSD) and an in-depth target from Incyte Genomics, Nucleic Acid
Res. 30 (2002) 137–141.
[48] M. Ashburner, et al., Gene Ontology: tool for the uniﬁcation of biology, Nat. Genet.
25 (2000) 25–29.
